Stephen R.D. Johnston, PhD
The combination of lapatinib (Tykerb), trastuzumab (Herceptin), and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer (MBC) compared with those treated with a targeted agent plus AI, according to findings published in the Journal of Clinical Oncology.
The most common any-grade adverse event (AE) in the triplet arm was diarrhea (69%), followed by rash (36%), nausea (22%), and paronychia (30%). Investigators reported that the frequency of grade 3/4 AEs was <5% across the 3 treatment arms except for diarrhea in the lapatinib/trastuzumab plus AI arm (13%) and the lapatinib plus AI arm (6%).
Johnston SRD, Hegg R, Im S, et al. Phase III, Randomized study of dual human epidermal growth factor receptor 2 (her2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with her2-positive, hormone receptor–positive metastatic breast cancer: ALTERNATIVE [published online December 15, 2017]. J Clin Oncol doi: 10.1200/JCO. 2017.74.7824.
... to read the full story